CD80 and neoplasm: The PD-L1/PD-1 and CD80/CTLA-4 interactions inhibit CD8+ cytotoxic T-lymphocyte proliferation and survival and affect the function of tumour-infiltrating T cells, which suppress the immune system and cause peripheral immune tolerance in cancer patients11.